Avastin bevacizumab regulatory update

FDA approved an sBLA from Roche's Genentech Inc. unit for Avastin bevacizumab to treat recurrent platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer in combination with paclitaxel, topotecan or pegylated liposomal doxorubicin. The humanized mAb against VEGF was under Priority Review for the indication. ...